

Tullio Palmerini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2340075/publications.pdf>

Version: 2024-02-01

18
papers

2,872
citations

567281

15
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

3511
citing authors

#	ARTICLE	IF	CITATIONS
1	In vitro thrombogenicity of drug-eluting and bare metal stents. <i>Thrombosis Research</i> , 2020, 185, 43-48.	1.7	5
2	Target Lesion Failure With Current Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2868-2878.	2.9	22
3	High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study. <i>International Journal of Cardiology</i> , 2018, 259, 20-25.	1.7	18
4	Response to Letter of Li et al.: How to select antiplatelet therapy in patients with acute coronary syndrome, according to platelet function testing or pharmacogenomic testing?. <i>International Journal of Cardiology</i> , 2018, 271, 30.	1.7	0
5	Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. <i>International Journal of Cardiology</i> , 2018, 268, 61-67.	1.7	46
6	Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1851-1864.	2.8	319
7	Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. <i>EuroIntervention</i> , 2016, 12, 312-318.	3.2	27
8	Bleeding and stent thrombosis on P2Y ₁₂ -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , 2015, 36, 1762-1771.	2.2	297
9	Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. <i>Lancet, The</i> , 2015, 385, 2371-2382.	13.7	345
10	The association between the extent of coronary artery disease and major bleeding events after percutaneous coronary intervention: from the ACUTY trial. <i>Journal of Invasive Cardiology</i> , 2015, 27, 203-11.	0.4	5
11	Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1117-1127.	2.9	38
12	Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1845-1854.	2.8	343
13	Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents. <i>Journal of the American College of Cardiology</i> , 2014, 63, 299-307.	2.8	269
14	Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2111-2118.	2.8	85
15	Stent Thrombosis With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1915-1921.	2.8	119
16	Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. <i>Lancet, The</i> , 2012, 379, 1393-1402.	13.7	854
17	Predictors and Implications of Stent Thrombosis in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 577-584.	3.9	38
18	Monocyte-derived tissue factor contributes to stent thrombosis in an in vitro system. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1570-1577.	2.8	42